SCHEMBL3092971

SCHEMBL3092971

CCN(C(=O)C(Cc1cccc(OCc2ccccc2)c1)C(=O)O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.50
MME P08473 1/20 0.50
ACE P12821 1/20 0.50
CPA1 P15085 1/20 0.50
ACE2 Q9BYF1 1/20 0.50
MAOB P27338 2/20 0.48
PTGES O14684 2/20 0.47
NR4A2 P43354 1/20 0.47
ALOX5 P09917 2/20 0.47
LTC4S Q16873 1/20 0.47
LTB4R Q15722 1/20 0.46
LTB4R2 Q9NPC1 1/20 0.46
GPR132 Q9UNW8 1/20 0.46
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
CYP2D6 P10635 1/20 0.45
NOX1 Q9Y5S8 1/20 0.45
FFAR1 O14842 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27787119 0.89 CYP4F2 (0.49) BCHEMMEACECPA1ACE2
SCHEMBL3086016 0.88 PPARA (0.54) MMEACECPA1ACE2MAOB
SCHEMBL3089145 0.82 PPARG (0.46) MMEACECPA1ACE2PTGES
SCHEMBL3090279 0.82 MME (0.42) BCHEMMEACECPA1ACE2
SCHEMBL3090281 0.82 MME (0.42) BCHEMMEACECPA1ACE2
SCHEMBL3097715 0.81 ALDH1A1 (0.45) PTGESMEN1TSHRKMT2A
SCHEMBL27787093 0.79 BCHE (0.53) BCHEALOX5LTB4RLTB4R2NOX1
SCHEMBL6691798 0.79 MAOB (0.62) BCHEMMEACECPA1ACE2
SCHEMBL28087440 0.76 MME (0.60) BCHEMMEACECPA1ACE2
SCHEMBL3079461 0.76 LDHA (0.64) BCHEALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 BCHE 2443/4885MME 14/4885ACE 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.